GO:2000811 negative regulation of anoikis: Cell Survival Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000811 (negative regulation of anoikis) describes any process that stops, prevents, or reduces the frequency, rate, or extent of anoikis, the detachment-induced cell death that occurs when cells lose integrin-mediated attachment to the extracellular matrix.
• Anoikis resistance is a hallmark of metastatic cancer cells and is frequently observed in triple-negative breast cancer (TNBC), colorectal cancer, and other aggressive malignancies [1,2,4].
• Key molecular drivers of negative regulation of anoikis include integrin signaling, growth factor receptor pathways, deubiquitinating enzymes such as OTUB1, and epigenetic regulators such as SIRT6 [3,6,8].
• MicroRNAs and long non-coding RNAs can modulate anoikis resistance by targeting pro-apoptotic or pro-survival transcripts, adding a layer of post-transcriptional control.
• Cell adhesion and cell density can suppress interferon-γ/STAT1 signaling, illustrating crosstalk between the physical environment and immune signaling in the regulation of anoikis.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of specific genes in negative regulation of anoikis and to identify therapeutic targets [2,4,6,8].
Description
Anoikis is a specialized form of programmed cell death that is triggered when cells detach from the extracellular matrix (ECM) or from neighboring cells. This process is essential for normal tissue homeostasis, development, and the prevention of ectopic cell growth. The Gene Ontology term GO:2000811, negative regulation of anoikis, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of anoikis. Understanding how cells evade anoikis is of major interest because anoikis resistance is a critical step in cancer metastasis, allowing tumor cells to survive in the circulation and colonize distant organs [1,5]. In triple-negative breast cancer (TNBC), for example, multiple signaling pathways and epigenetic regulators contribute to anoikis resistance, making it a promising therapeutic target [1,2,6]. Similarly, in colorectal cancer, proteins such as SIRT6 and INHBB have been shown to promote anoikis resistance and metastasis [4,8]. This article provides a research-grade overview of GO:2000811, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental approaches, including CRISPR-based models and EDITGENE services.
negative regulation of anoikis At A Glance
| GO ID | GO:2000811 |
|---|---|
| GO term | negative regulation of anoikis |
| Ontology | biological_process |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of anoikis. |
| Synonym | negative regulation of detachment induced cell death; negative regulation of suspension induced apoptosis |
| Major function | Promotes cell survival upon loss of ECM attachment, contributing to metastasis and tissue remodeling. |
| Related processes | Anoikis, cell adhesion, apoptosis, epithelial-mesenchymal transition (EMT), metastasis. |
| Key regulators | Integrins, growth factor receptors, OTUB1, SIRT6, microRNAs, STAT1 signaling. |
| Disease relevance | Cancer metastasis, particularly triple-negative breast cancer and colorectal cancer. |
What Is GO:2000811?
GO:2000811, negative regulation of anoikis, is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of anoikis. In other words, it encompasses all molecular and cellular events that allow a cell to survive when it would otherwise undergo detachment-induced cell death. This includes signaling pathways activated by integrins, growth factor receptors, and oncogenes, as well as epigenetic and post-transcriptional mechanisms that suppress pro-apoptotic signals [1,3,5].
Why Is negative regulation of anoikis Important in Cell Biology?
Negative regulation of anoikis is critically important because it enables cells to survive in the absence of proper ECM attachment, a capability that is exploited by cancer cells during metastasis [1,3]. In normal development, anoikis prevents cells from growing in inappropriate locations, but cancer cells often acquire anoikis resistance through genetic and epigenetic changes, allowing them to disseminate and form secondary tumors [1,5]. Understanding the molecular mechanisms that negatively regulate anoikis can reveal new therapeutic targets to block metastasis and overcome drug resistance [2,4,6,8].
• Anoikis resistance is a key hallmark of metastatic cancer cells, enabling survival in the bloodstream and colonization of distant organs [1,3].
• Triple-negative breast cancer (TNBC) frequently exhibits anoikis resistance driven by multiple pathways, including OTUB1/TAZ and PTPN14 loss [2,6].
• Colorectal cancer metastasis to the liver is promoted by INHBB via TGF-β/Smad signaling and anoikis resistance.
• SIRT6-mediated downregulation of NDRG1 inhibits anoikis in colorectal cancer cells, highlighting epigenetic control.
• MicroRNAs can regulate anoikis resistance by targeting pro-apoptotic or pro-survival genes, offering potential therapeutic targets.
• Cell adhesion and density-dependent STAT1 dephosphorylation link the physical microenvironment to immune signaling and anoikis regulation.
• Integrin signaling is a central mechanism for suppressing anoikis, and its disruption can sensitize cells to detachment-induced death.
• Understanding negative regulation of anoikis can inform the development of anti-metastatic therapies that force cancer cells to undergo anoikis [1,2].
• CRISPR screens can identify novel regulators of anoikis resistance, accelerating target discovery [2,4,6,8].
• Anoikis resistance also plays roles in fibrosis and tissue remodeling, beyond cancer.
What Happens During negative regulation of anoikis?
Integrin-Mediated Survival Signaling
In simple terms: When cells stick to the matrix, integrins send survival signals; blocking anoikis means keeping these signals active even without attachment.
Integrins are transmembrane receptors that mediate cell-ECM adhesion and activate pro-survival pathways such as FAK, Src, and PI3K/AKT. Under normal conditions, loss of integrin engagement leads to anoikis, but cancer cells can maintain integrin signaling or activate compensatory pathways to survive detachment [1,3]. For example, in TNBC, integrin signaling contributes to anoikis resistance and metastasis.
Growth Factor and Cytokine Signaling
In simple terms: Growth factors can act as survival signals that prevent cells from dying when they detach.
Growth factor receptors, such as EGFR and IGF-1R, can activate downstream pathways that suppress anoikis. In colorectal cancer, INHBB promotes liver metastasis via TGF-β/Smad signaling, EMT, and anoikis resistance. Similarly, interferon-γ/STAT1 signaling can be modulated by cell adhesion and density, affecting anoikis sensitivity.
Deubiquitination and Protein Stability
In simple terms: Some enzymes remove ubiquitin tags from proteins, stabilizing them and promoting survival.
OTUB1 is a deubiquitinating enzyme that stabilizes TAZ, a transcriptional co-activator, thereby promoting anoikis resistance in basal-like TNBC cells. This illustrates how post-translational modifications can negatively regulate anoikis by altering the stability of key survival factors.
Epigenetic and Transcriptional Control
In simple terms: Epigenetic changes can turn survival genes on or off, helping cells avoid anoikis.
SIRT6, a histone deacetylase, inhibits anoikis in colorectal cancer cells by down-regulating NDRG1. This epigenetic regulation highlights the role of chromatin-modifying enzymes in negative regulation of anoikis. Additionally, microRNAs can post-transcriptionally regulate anoikis resistance by targeting mRNAs encoding pro-apoptotic proteins.
Metabolic and Stress Adaptation
In simple terms: Cells can adapt their metabolism to survive detachment-induced stress.
Although specific metabolic regulators of anoikis are not detailed in the provided citations, general mechanisms of anoikis resistance often involve adaptation to oxidative stress and metabolic reprogramming. Further research is needed to fully elucidate these pathways.
Key Genes Involved in GO:2000811 negative regulation of anoikis
The following genes and proteins have been experimentally implicated in the negative regulation of anoikis, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ITGB1 | Integrin beta-1; mediates cell-ECM adhesion and survival signaling | Central to anoikis suppression; target for metastasis studies |
| PTK2 | Focal adhesion kinase (FAK); transmits integrin survival signals | Key effector of anoikis resistance; druggable target |
| PIK3CA | PI3K catalytic subunit; activates AKT pro-survival pathway | Frequently mutated in cancers with anoikis resistance |
| AKT1 | Serine/threonine kinase; promotes cell survival | Downstream of integrins and growth factors; anoikis inhibitor |
| OTUB1 | Deubiquitinating enzyme; stabilizes TAZ | Promotes anoikis resistance in basal-like TNBC |
| TAZ | Transcriptional co-activator; downstream of OTUB1 | Mediates anoikis resistance in TNBC |
| PTPN14 | Protein tyrosine phosphatase; tumor suppressor | Loss leads to anoikis resistance in TNBC; restoration is antitumor |
| SIRT6 | NAD+-dependent deacetylase; epigenetic regulator | Inhibits anoikis in colorectal cancer via NDRG1 downregulation |
| NDRG1 | Stress-response protein; pro-apoptotic under some conditions | Downregulated by SIRT6 to promote anoikis resistance |
| INHBB | Inhibin subunit beta B; TGF-β superfamily ligand | Promotes liver metastasis and anoikis resistance in CRC |
| STAT1 | Signal transducer and activator of transcription 1 | Modulated by cell adhesion; affects anoikis sensitivity |
| MIR21 | MicroRNA-21; targets pro-apoptotic genes | Contributes to anoikis resistance in various cancers |
| MIR200 | MicroRNA-200 family; regulates EMT | Linked to anoikis resistance and metastasis |
| CDH1 | E-cadherin; cell-cell adhesion | Loss associated with EMT and anoikis resistance |
| VIM | Vimentin; mesenchymal marker | Upregulated in EMT and anoikis-resistant cells |
| TGFB1 | Transforming growth factor beta 1 | Induces EMT and anoikis resistance in CRC |
| SMAD2/3 | TGF-β signaling effectors | Mediate INHBB-induced anoikis resistance |
| EGFR | Epidermal growth factor receptor | Growth factor signaling that suppresses anoikis |
How Is negative regulation of anoikis Regulated?
Negative regulation of anoikis is controlled by a complex network of signaling pathways, including integrin-mediated adhesion signaling, growth factor receptor pathways (e.g., EGFR, IGF-1R), TGF-β/Smad signaling, and epigenetic modifiers such as SIRT6 [1,3,4,8]. Deubiquitinating enzymes like OTUB1 stabilize survival factors such as TAZ, while microRNAs fine-tune the expression of pro- and anti-apoptotic genes [5,6]. Additionally, cell adhesion and density can modulate STAT1 phosphorylation, linking the physical microenvironment to immune signaling. These regulatory layers ensure that cells can survive detachment under specific conditions, such as during metastasis.
negative regulation of anoikis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OTUB1 | Triple-negative breast cancer; anoikis resistance | Knockout in TNBC cell lines (e.g., MDA-MB-231) |
| PTPN14 | TNBC; tumor suppression | Overexpression via mRNA-LNP; knockout to assess anoikis |
| SIRT6 | Colorectal cancer; anoikis inhibition | Knockout in HCT116 or SW480 cells |
| INHBB | Colorectal cancer liver metastasis | Knockout in CRC cells; mouse metastasis models |
| STAT1 | Cell adhesion-dependent signaling | Point mutation of phosphorylation sites; KO cells |
Triple-Negative Breast Cancer (TNBC)
TNBC is an aggressive subtype of breast cancer with limited targeted therapies. Anoikis resistance is a hallmark of TNBC, enabling metastasis. Key regulators include OTUB1, which stabilizes TAZ to promote anoikis resistance, and PTPN14, whose loss contributes to anoikis resistance; restoration of PTPN14 via mRNA-lipid nanoparticles exhibits antitumor effects. Integrin signaling and growth factor pathways also play roles.
Colorectal Cancer (CRC)
In CRC, anoikis resistance facilitates liver metastasis. INHBB promotes metastasis via TGF-β/Smad signaling, EMT, and anoikis resistance. SIRT6 inhibits anoikis by down-regulating NDRG1, contributing to tumor cell survival. These findings highlight potential therapeutic targets to block CRC metastasis.
Other Cancers and Metastasis
Anoikis resistance is a general mechanism in many cancers, including lung, prostate, and pancreatic cancer. MicroRNAs such as miR-21 and miR-200 family members regulate anoikis resistance and EMT, influencing metastatic potential. Understanding these pathways is crucial for developing anti-metastatic therapies.
From negative regulation of anoikis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of gene X sensitize cells to anoikis? | CRISPR knockout in cancer cell lines, followed by anoikis assays [2,6,8] |
| Does a specific mutation in gene Y affect anoikis resistance? | CRISPR point mutation knock-in of the mutation |
| Does overexpression of gene Z promote anoikis resistance? | CRISPR knock-in of a constitutive promoter or cDNA overexpression |
| How does a tagged version of protein W behave during anoikis? | CRISPR knock-in of an epitope tag (e.g., FLAG, HA) |
| Which genes are essential for anoikis resistance in a genome-wide manner? | CRISPR library screening with anoikis selection |
| Can restoration of a tumor suppressor reverse anoikis resistance? | CRISPR-mediated knock-in or mRNA-LNP delivery |
How to Study the negative regulation of anoikis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Suspension culture + viability assay | Cell survival under detachment | Anoikis resistance screening [1,2] |
| CRISPR knockout screen | Genes essential for anoikis resistance | Genome-wide target discovery |
| RNA-seq | Transcriptional changes during anoikis | Identify survival pathways [1,4] |
| Phosphoproteomics | Signaling changes (e.g., STAT1) | Adhesion-dependent signaling |
| Western blot | Protein expression and modification | Validate key regulators [6,8] |
| Immunofluorescence | Protein localization | Study TAZ, SIRT6 in detached cells [6,8] |
| Flow cytometry | Apoptosis and cell cycle | Quantify anoikis |
| Mouse metastasis models | In vivo anoikis resistance | Test therapeutic targets [2,4] |
Anoikis Assays
Anoikis is typically assessed by culturing cells in suspension or on poly-HEMA-coated plates to prevent attachment, followed by viability assays (e.g., MTT, CellTiter-Glo) or apoptosis markers (caspase-3/7 activity, Annexin V staining) [1,2,6]. These assays are fundamental to studying negative regulation of anoikis.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain affects anoikis resistance. Cells are cultured under detachment conditions, and sgRNAs enriched in surviving cells are sequenced. This approach has uncovered novel regulators in various cancers.
Transcriptomics and Proteomics
RNA-seq and proteomics can compare attached vs. detached cells to identify differentially expressed genes and proteins involved in anoikis resistance [1,4]. Phosphoproteomics can reveal signaling changes, such as STAT1 dephosphorylation.
Imaging and Live-Cell Analysis
Live-cell imaging can track cell survival and death under detachment conditions, while immunofluorescence can localize proteins such as TAZ or SIRT6 [6,8]. These methods provide spatial and temporal insights into anoikis regulation.
How CRISPR Can Be Used to Study GO:2000811 negative regulation of anoikis
Knockout
CRISPR knockout is used to delete genes of interest and assess their role in anoikis resistance. For example, knockout of OTUB1 in TNBC cells reduces TAZ levels and increases anoikis. Similarly, SIRT6 knockout in colorectal cancer cells affects NDRG1 expression and anoikis sensitivity. Knockout models are essential for establishing causality.
Point Mutation
CRISPR point mutation knock-in introduces specific nucleotide changes to study phosphorylation sites or catalytic residues. For instance, mutating STAT1 phosphorylation sites can reveal how adhesion-dependent dephosphorylation regulates anoikis. This approach provides mechanistic insights into signaling pathways.
Knock-in
CRISPR knock-in can insert tags (e.g., FLAG, HA) or reporter genes to track protein localization and interactions. Tagging endogenous TAZ or SIRT6 allows real-time monitoring during anoikis [6,8]. Knock-in of mutant alleles can also model disease-associated variants.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can elevate gene expression to test gain-of-function effects. Overexpressing PTPN14 via mRNA-LNP restores anoikis and suppresses tumor growth in TNBC. Overexpression models are useful for validating tumor suppressors and survival factors.
How EDITGENE Supports negative regulation of anoikis Research
Researchers studying negative regulation of anoikis-related genes often need to determine whether a candidate gene is causally involved in anoikis resistance or is merely a bystander. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of anoikis research.
Frequently Asked Questions About negative regulation of anoikis
What is negative regulation of anoikis?
Negative regulation of anoikis (GO:2000811) refers to any process that stops, prevents, or reduces the frequency, rate, or extent of anoikis, the detachment-induced cell death.
What genes are involved in negative regulation of anoikis?
Key genes include OTUB1, TAZ, PTPN14, SIRT6, NDRG1, INHBB, STAT1, and various microRNAs such as miR-21 [2,4,5,6,7,8].
How is anoikis resistance related to cancer metastasis?
Anoikis resistance allows cancer cells to survive after detaching from the primary tumor, facilitating travel through the bloodstream and colonization of distant organs [1,3].
What is the role of OTUB1 in anoikis resistance?
OTUB1 is a deubiquitinating enzyme that stabilizes TAZ, promoting anoikis resistance in basal-like triple-negative breast cancer cells.
How does SIRT6 inhibit anoikis?
SIRT6 inhibits anoikis in colorectal cancer cells by down-regulating NDRG1, thereby promoting cell survival.
Can CRISPR be used to study negative regulation of anoikis?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect gene function in anoikis resistance [2,4,6,8].
What is the connection between INHBB and anoikis resistance?
INHBB promotes liver metastasis of colorectal cancer via TGF-β/Smad signaling, EMT, and anoikis resistance.
How does cell adhesion affect STAT1 signaling in anoikis?
Cell adhesion and cell density can lead to STAT1 dephosphorylation, negatively regulating interferon-γ/STAT1 signaling and influencing anoikis.
What experimental models are used to study anoikis resistance?
Common models include suspension culture, CRISPR screens, RNA-seq, proteomics, and mouse metastasis models [1,2,5].
What services does EDITGENE offer for anoikis research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services to study anoikis-related genes.
Conclusion
Negative regulation of anoikis (GO:2000811) is a critical biological process that enables cells to survive detachment from the extracellular matrix, a capability that is hijacked by cancer cells to metastasize. Key regulators such as OTUB1, TAZ, PTPN14, SIRT6, and INHBB have been identified through molecular and functional studies, revealing potential therapeutic targets. CRISPR-based models and high-throughput screening are indispensable for dissecting these pathways and identifying new interventions. EDITGENE offers comprehensive services to support researchers in this field, from custom cell line generation to bioinformatics analysis.
References
- 1. Tajbakhsh A et al.. 2019. Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review.. Crit Rev Oncol Hematol 140:17-27 PMID: 31154235
- 2. Li W et al.. 2024. mRNA-Lipid Nanoparticle-Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple-Negative Breast Cancer.. Adv Sci (Weinh) 11(32):e2309988 PMID: 39189475
- 3. Frisch SM et al.. 1997. Integrins and anoikis.. Curr Opin Cell Biol 9(5):701-6 PMID: 9330874
- 4. Yang N et al.. 2026. INHBB promotes liver metastasis of colorectal cancer via regulation of TGF-β/Smad signaling, EMT and anoikis resistance.. Tissue Cell 99:103258 PMID: 41380489
- 5. Chan SH et al.. 2015. Regulation of cancer metastasis by microRNAs.. J Biomed Sci 22(1):9 PMID: 25614041
- 6. Nakagawa H et al.. 2023. An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells.. Biochem Biophys Res Commun 649:1-9 PMID: 36738577
- 7. Chen Z et al.. 2011. Negative regulation of interferon-γ/STAT1 signaling through cell adhesion and cell density-dependent STAT1 dephosphorylation.. Cell Signal 23(8):1404-12 PMID: 21511030
- 8. Li F et al.. 2024. SIRT6 Inhibits Anoikis of Colorectal Cancer Cells by Down-Regulating NDRG1.. Int J Mol Sci 25(11) PMID: 38891773
